You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hypomethylating agent

Showing 1 - 25 of 6,299
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

Recruiting
  • Hypomethylating Agent
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Jiao Tong University School of Medicine Affilated Shang
May 2, 2023

AML, MDS Trial in Houston (Vibecotamab, Dexamethasone, Acetaminophen)

Recruiting
  • AML
  • MDS
  • Houston, Texas
    M D Anderson Cancer Center
Sep 29, 2022

Pancreas Cancer Trial in New York (Pembrolizumab, Azacitidine)

Active, not recruiting
  • Pancreas Cancer
  • New York, New York
    Columbia University Irving Medical Center
Nov 29, 2022

MDS Trial in New Haven (CPX-351)

Withdrawn
  • MDS
  • New Haven, Connecticut
    Yale University; Smilow Cancer Center
Jan 6, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Los Angeles, Sacramento, Oklahoma City (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • Recurrent Acute Myeloid Leukemia
  • Los Angeles, California
  • +2 more
Mar 11, 2022

Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • Maywood, Illinois
    Loyola University Medical Center
Aug 1, 2023

Myelodysplastic Syndrome (MDS) Trial in Cleveland (CPX-351)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Apr 21, 2021

Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer Trial in United States (Guadecitabine, Carboplatin)

Active, not recruiting
  • Small Cell Lung Cancer
  • Extensive-stage Small Cell Lung Cancer
  • Indianapolis, Indiana
  • +3 more
Feb 14, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia

Recruiting
  • Myelodysplastic Syndrome
  • +2 more
  • Navitoclax
  • +6 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute

Recruiting
  • Acute Myeloid Leukemia, Adult
  • +2 more
  • Trieste, Italy
    SC Ematologia Ospedale Maggiore
Sep 14, 2020

Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor Positive and

Completed
  • Microsatellite Stable Colorectal Carcinoma
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Mar 30, 2021

Leukemia Trial in Houston (Eltrombopag, Hypomethylating Agent (HMA))

Completed
Has Results
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 5, 2020

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue

Withdrawn
  • Castration Levels of Testosterone
  • +8 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Mar 31, 2021

Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive

Unknown status
  • Acute Myeloid Leukemia, in Relapsed or Refractory
  • +2 more
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Sep 8, 2020

MDS, CMML, AML Trial in Canada, United States (SGI-110)

Completed
  • MDS
  • +2 more
  • Scottsdale, Arizona
  • +15 more
Apr 16, 2021

Acute Myeloid Leukemia Trial in Germany (Venetoclax plus Azacitidine, standard of care chemo plus gemtuzumab ozogamicin)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Venetoclax plus Azacitidine
  • standard of care chemotherapy plus gemtuzumab ozogamicin
  • Essen, NRW, Germany
  • +17 more
Jun 6, 2023

Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome, Low-risk Myelodysplastic Syndrome Trial in France, Germany,

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Nantes, Nantes Cedex 1, France
  • +7 more
Dec 20, 2021

Acute Myeloid Leukemia Trial in NanJing (Homoharringtonine, Azacitidine)

Recruiting
  • Acute Myeloid Leukemia
  • NanJing, China
    Department of Hematology, Zhongda Hospital, Medical School of So
Sep 2, 2022

Strategy for High-Risk Myelodysplastic Syndromes in Patients

Active, not recruiting
  • Myelodysplastic Syndromes
  • Allogeneic Stem Cell Transplantation
  • Agen, France
  • +9 more
Jul 5, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
Has Results
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Optimize Treatment Strategies for Older Hematologic Malignancies

Recruiting
  • Leukemia, Acute
  • MDS
  • Bone Marrow or Peripheral Blood Graft (BMT)
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 7, 2022

Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,

Terminated
  • Advanced Solid Tumor
  • +3 more
  • Darlinghurst, New South Wales, Australia
  • +1 more
Dec 18, 2022

Myelodysplastic Syndrome Trial in New York (Vosaroxin)

Completed
Has Results
  • Myelodysplastic Syndrome
  • New York, New York
    Weill Cornell Medical College
Jan 24, 2019

MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 30, 2023